HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Venous access in pediatric oncology patients.

AbstractLong-term central venous access is an integral part of the management of many, but not all children with cancer. The proper selection of those children who require this access and which access device (external vs. totally implanted) is best suited to that child is important to minimize complications and obtain optimal results. Although most of these devices can be expected to last the duration of the treatment protocol or the patient's life, complications (infection, occlusion, dislodgment) occur with higher than desired frequency, infection being the most common. No measures are clearly beneficial in preventing infection, but most infections can be treated successfully without device removal. Premature removal or dislodgement occurs more frequently with external catheters and may be minimized by techniques used at insertion. Occlusion, detected early, can be successfully managed by clot lysis in most children.
AuthorsC T Albanese, E S Wiener (Affiliation: Department of Pediatric Surgery, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pennsylvania 15213-2583.)
JournalSeminars in surgical oncology (Semin Surg Oncol) 1993 Nov-Dec Vol. 9 Issue 6 Pg. 467-77 ISSN: 8756-0437 [Print] UNITED STATES
PMID8284565 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
Chemical References
  • Urokinase-Type Plasminogen Activator
Topics
  • Catheterization, Central Venous (adverse effects, instrumentation)
  • Catheters, Indwelling (adverse effects)
  • Child
  • Child, Preschool
  • Equipment Failure
  • Humans
  • Infant
  • Infection (drug therapy, etiology)
  • Neoplasms (surgery, therapy)
  • Prostheses and Implants
  • Urokinase-Type Plasminogen Activator (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $45.00 USD